The global stented biological valve market size was valued at USD 2.76 billion in 2024. The market is projected to grow from USD 2.94 billion in 2025 to USD 4.25 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.
Access Full Research Report: Stented Biological Valve Market – Detailed Analysis
What Are Stented Biological Valves?
Stented biological valves represent an innovative class of heart valve prosthetics crafted from animal tissues (typically bovine pericardium or porcine valves) integrated with a structural metal or polymer stent framework. These devices have become the preferred solution for patients who cannot tolerate long-term anticoagulation therapy required by mechanical alternatives. The stent component facilitates precise implantation during both conventional surgical aortic valve replacement (SAVR) and minimally invasive transcatheter aortic valve replacement (TAVR) procedures.
Stented biological valves are bioprosthetic heart valves made from animal tissues (bovine or porcine) with an integrated metallic or polymeric stent structure. These valves are primarily used in patients requiring valve replacement who cannot tolerate long-term anticoagulation therapy. The stent provides structural support, facilitating precise implantation during surgical or transcatheter procedures. The global stented biological valve market is experiencing significant growth, driven by the increasing prevalence of valvular heart diseases, advancements in surgical techniques, and a rising geriatric population. Stented tissue valves, which include bovine and porcine valves, are widely utilized in heart valve replacement procedures due to their durability and compatibility with the human body. These valves are supported by a metal or polymer frame (stent) that helps in maintaining the valve’s shape and facilitating its placement. According to the United Nation Department of Economic and Social Affairs, In 2020, there are an estimated 727 million persons aged 65 years or over worldwide. This number is projected to more than double by 2050, reaching over 1.5 billion persons
MARKET DYNAMICS MARKET DRIVERS
Growing Preference for Biological Valves Over Mechanical Valves to Boost Market Expansion
The stented biological valve market is experiencing significant growth due to the increasing preference for biological valves over mechanical alternatives. Biological valves, derived from bovine or porcine tissues, offer patients the advantage of not requiring long-term anticoagulation therapy – a necessity with mechanical valves that significantly impacts quality of life. Recent clinical studies show that approximately 65% of aortic valve replacements in patients over 70 now utilize biological options due to these benefits. The stent framework provides structural support during implantation while maintaining natural hemodynamics, making them particularly suitable for elderly patients and those with contraindications to blood thinners.
Rising Adoption of TAVR Procedures Accelerating Market Growth
Transcatheter aortic valve replacement (TAVR) procedures are transforming the treatment paradigm for valvular heart disease, driving substantial demand for stented biological valves. Unlike traditional open-heart surgeries, TAVR offers minimally invasive implantation with faster recovery times and reduced complication rates. Market data indicates TAVR procedures grew by over 22% annually in major markets between 2020-2023, with stented valves representing approximately 80% of these interventions. This shift is particularly impactful as cardiovascular diseases continue to rise globally, with valvular heart disease affecting an estimated 2.5% of the population in developed nations.
Aging Population and Increased Valvular Disease Prevalence Strengthening Market Position
The global demographic shift toward an older population is creating sustained demand for stented biological valves. With age being the primary risk factor for degenerative valve disease, the over-65 population – projected to reach 1.6 billion by 2050 – represents a key patient cohort. Simultaneously, improved diagnostic capabilities have led to earlier detection of valve disorders, expanding the eligible treatment population. Clinical evidence shows that patients aged 60-80 experience superior outcomes with stented biological valves compared to mechanical alternatives, given reduced bleeding risks and avoidance of anticoagulation therapy.On 1 January 2024, the EU population was estimated at 449.3 million people and more than one-fifth (21.6%) of it was aged 65 years and over.According to a research study valvular heart disease, affecs an estimated 3–5% of the general population.
MARKET OPPORTUNITIES
Expanding TAVR Indications Opening New Market Segments
The recent FDA approval of TAVR for lower-risk patients presents significant growth opportunities for stented biological valve manufacturers. Originally limited to high-risk surgical candidates, TAVR indications now encompass intermediate and low-risk patients, potentially quadrupling the addressable market. Clinical trials demonstrate excellent outcomes in these expanded populations, with recent data showing comparable 5-year survival rates between TAVR and surgical aortic valve replacement (SAVR) in low-risk cohorts. This regulatory expansion is prompting manufacturers to develop specialized valve designs optimized for broader patient demographics.
Technological Innovations in Valve Design Enhancing Market Potential
Ongoing research into next-generation stented valves is creating exciting market opportunities through improved durability and performance. Recent advancements include tissue treatment technologies that reduce calcification, novel stent designs for enhanced leaflet dynamics, and hybrid materials combining synthetic and biological components. Clinical trials of these next-gen valves show promising results, with some demonstrating 85% freedom from SVD at 10 years compared to 65-70% for current standard valves. As these innovations translate to commercial products, they may significantly extend appropriate usage across younger patient populations.
October 2023, Edwards Lifesciences announced that its has received CE Mark approval for its EVOQUE tricuspid valve replacement system, marking it the world’s first transcatheter valve replacement therapy approved for tricuspid regurgitation treatmen.
List of Key Stented Biological Valve Companies Profiled
- Medtronic PLC (Ireland)
- Edwards Lifesciences Corporation (U.S.)
- St. Jude Medical (Abbott) (U.S.)
- Meril Life Sciences (India)
- Boston Scientific Corporation (U.S.)
- Laboratoires Cryolife (France)
- Abbott Laboratories (U.S.)
- Colibri Heart Valve (U.S.)
- Balance Medical (China)
- Venus Medtech (China)
- Suzhou Jiecheng Medical Technology (China)
The competitive intensity in the stented biological valve market shows no signs of abating, with companies increasingly focusing on developing valves suitable for younger patient populations through advanced tissue engineering technologies. Furthermore, the shift toward minimally invasive procedures continues to reshape competitive dynamics, favoring players with strong interventional cardiology portfolios.
Segment Analysis:
By Type
Aortic Valve Replacement (AVR) Segment Holds Major Market Share Due to High Adoption in Traditional Open-Heart Procedures
The market is segmented based on type into:
- Aortic Valve Replacement (AVR)
- Mitral Valve Replacement (MVR)
- Pulmonary Valve Replacement (PVR)
- Tricuspid Valve Replacement (TVR)
By Application
Hospital Segment Dominates Market Share Owing to Growing Number of Valve Replacement Surgeries
The market is segmented based on application into:
- Hospital
- Clinic
- Ambulatory Surgical Centers (ASCs)
- Other
By Material
Bovine Pericardial Valves Lead Due to Superior Durability and Hemodynamic Performance
The market is segmented based on material into:
- Bovine pericardial tissue
- Porcine tissue
- Synthetic materials
By Procedure
TAVR Segment Shows Robust Growth Fueled by Minimally Invasive Approach Advantages
The market is segmented based on procedure into:
- Surgical Aortic Valve Replacement (SAVR)
- Transcatheter Aortic Valve Replacement (TAVR)
Recent Developments
- Next-Gen Tissue Processing: Companies are adopting anti-calcification treatments and enhanced tissue preservation methods to extend valve durability and performance.
- Minimally Invasive Expansion: Growing use of transcatheter aortic valve replacement (TAVR) procedures with stented biological valves, reducing surgical risks for high-risk patients.
- Hybrid Valve Designs: Introduction of bioprosthetic valves with synthetic reinforcements to improve hemodynamics and longevity compared to traditional models.
- Regulatory Approvals: Several leading players received FDA and CE Mark approvals for new stented biological valve systems designed for both aortic and mitral applications.
- Pediatric & Young Adult Research: Ongoing trials exploring next-gen stented bioprostheses aimed at extending use in younger patients with reduced reoperation risk.
- Digital Surgical Planning: Integration of AI-driven imaging and 3D printing to optimize pre-surgical planning and ensure precise valve sizing and placement.
- Global Market Expansion: Manufacturers are expanding production and distribution facilities in Asia-Pacific and Latin America to meet rising demand.
- Strategic Partnerships & Acquisitions: Medical device companies are partnering with cardiovascular research institutes and acquiring niche valve technology firms to strengthen portfolios.
- Focus on Long-Term Outcomes: Multiple clinical studies and registries are reporting improved mid- to long-term outcomes of new-generation stented bioprosthetic valves.
- Sustainability Trends: Some companies are exploring eco-friendly sourcing and processing of biological tissues to align with healthcare sustainability initiatives.
STENTED BIOLOGICAL VALVE MARKET TRENDS
Growing Adoption of TAVR Procedures to Drive Market Expansion
The global stented biological valve market is witnessing transformative growth, fueled by the rising adoption of transcatheter aortic valve replacement (TAVR) procedures. TAVR, a minimally invasive alternative to open-heart surgery, has revolutionized the treatment of aortic valve stenosis, particularly in elderly and high-risk patients. Stented biological valves, specifically designed for TAVR, dominate this space due to their ease of implantation and superior hemodynamic performance. Recent studies indicate that over 150,000 TAVR procedures are performed annually worldwide, with adoption rates growing at approximately 12% year-over-year in key markets. Manufacturers are now focusing on developing next-generation stented valves with enhanced durability and expanded indications for younger patient populations.
Report Coverage
This comprehensive analysis provides:
- Historical data and 2025-2032 forecasts
- In-depth competitive intelligence
- SWOT and value chain analysis
- Detailed market segmentation
- Regional opportunity mapping
Access Full Research Report: Stented Biological Valve Market – Detailed Analysis
About Intel Market Research
Intel Market Research delivers actionable insights in technology and infrastructure markets. Our data-driven analysis leverages:
- Real-time infrastructure monitoring
- Techno-economic feasibility studies
Competitive intelligence across 100+ countries
Trusted by Fortune 500 firms, we empower strategic decisions with precision.
International: +1(332) 2424 294 | Asia: +91 9169164321
Website: https://www.intelmarketresearch.com
Follow us on LinkedIn: https://www.linkedin.com/company/intel-market-research
